Journal article

Therapeutic options for mucinous ovarian carcinoma

Kylie L Gorringe, Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, David DL Bowtell, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Sian Fereday, C Blake Gilks, Charlie Gourley, Alison M Hadley, Joy Hendley, Sally M Hunter, Scott H Kaufmann Show all

GYNECOLOGIC ONCOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2020

Abstract

OBJECTIVE: Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival. There are no current guidelines specifically for the systemic management of recurrent MOC. We analyzed data from a large cohort of women with MOC to evaluate the potential for clinical utility from a range of systemic agents. METHODS: We analyzed gene copy number (n = 191) and DNA sequencing data (n = 184) from primary MOC to evaluate signatures of mismatch repair deficiency..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by Victorian Cancer Agency


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by Cancer Foundation of Western Australia


Awarded by National Health and Medical Research Council of Australia


Awarded by Gynaecological Oncology Biobank at Westmead - National Health and Medical Research Council Enabling Grants


Awarded by Cancer Institute NSW


Awarded by Mayo Clinic: National Institutes of Health


Funding Acknowledgements

This study was supported by the National Health and Medical Research Council of Australia (NHMRC) Grants #APP1045783 and #628434, the Victorian Cancer Agency (Clinical Fellowships to CLS CRF10-20, CRF16014), Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to CLS); the Peter MacCallum Cancer Foundation, and the Stafford Fox Medical Research Foundation. This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. The Bioinformatics and Molecular Genomics Core Facilities of the Peter MacCallum Cancer Centre were supported by the Australian Cancer Research Foundation.CASCADE: Supported by the Peter MacCallum Cancer Foundation.AOCS: The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi -State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID400413 and ID400281).The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org.We would like to thank all of the women who participated in these research programs.COEUR: This study uses resources provided by the Canadian Ovarian Cancer Research Consortium's - COEUR biobank funded by the Terry Fox Research Institute and managed and supervised by the Centre hospitalier de l'Universite de Montreal (CRCHUM). The Consortium acknowledges contributions to its COEUR biobank from Institutions across Canada (for a full list see http://www.tfri.ca/en/research/translationalresearch/coeur/coeur_biobanks.aspx).The Gynaecological Oncology Biobank at Westmead is a member of the Australasian Biospecimen Network-Oncology group, which was funded by the National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grants ID 12/RIG/1-17 & 15/RIG/1-16.OVCARE receives core funding from The BC Cancer Foundation and the VGH and UBC Hospital Foundation.Mayo Clinic: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation.Edinburgh: We extend our thanks to the Edinburgh Ovarian Cancer Database from which data were collected for this research and the Nicola Murray Foundation for supporting the Nicola Murray Centre for Ovarian Cancer Research.